肿瘤细胞治疗研究
英文原题：GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.
G蛋白偶联受体C类第5组成员D（GPRC5D）已成为复发/难治性多发性骨髓瘤中一个关键的免疫治疗靶点。
G蛋白偶联受体C类第5组成员D（GPRC5D）已成为复发/难治性多发性骨髓瘤中一个关键的免疫治疗靶点。尽管T细胞衔接双特异性抗体talquetamab是目前唯一获批的抗GPRC5D疗法，但众多有前景的药物正在进行临床评估。虽然抗GPRC5DCAR-T 细胞显示出潜力，但本综述特别聚焦于T细胞衔接双特异性和三特异性抗体。我们重点阐述GPRC5D在临床上与B细胞成熟抗原的差异，探讨耐药机制，讨论新型治疗策略包括联合方案及talquetamab作为CAR-T 细胞桥接治疗，并综述目前正在开发中的关键在研T细胞衔接器。
G-protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a crucial immunotherapy target in relapsed/refractory multiple myeloma. Although the T-cell-engaging bispecific antibody talquetamab is currently the only approved anti-GPRC5D therapy, numerous promising agents are undergoing clinical evaluation. While anti-GPRC5D chimeric antigen receptor T cells show potential, this review focuses specifically on T-cell-engaging bispecific and trispecific antibodies. We highlight how GPRC5D differs clinically from B-cell maturation antigen, explore mechanisms of resistance, discuss novel therapeutic strategies including combination regimens and talquetamab as bridging therapy to chimeric antigen receptor T cells, and review key investigational T-cell engagers currently in development.
MEMBER ACCOUNT
登录成功会直接打开下一页。
